SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme
35A Boulevard Joseph II, L-1840 Luxembourg
Sub: Earnings Conference Call
Dear Sir / Madam,
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 25th January, 2023.
This is for your information and records.
Thanking you,
Yours faithfully,
For Cipla Limited
RAJENDR
KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA Date: 2023.01.11 12:40:30 +05'30'
Rajendra Chopra
Company Secretary
Encl.: as above
Prepared by: Juzer Masta
Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 24826000 F +91 22 24826120 Wwww.cipla.com E-mailcontactus@cipla.comCorporate Identity Number L24239MH1935PLC002380
Announcement
Cipla to release Q3FY23 Unaudited Financial Results on January 25, 2023
Date: January 25, 2023
1630 hrs IST - EARNINGS CONFERENCE CALL
The Company will host an earnings conference call at 1630 hrs IST (1900 hrs SST/HKT, 1100 hrs BST, 0600 hrs US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.cipla.com.
Earnings Conference Call Dial-in Information
Date and Time
January 25, 2023 at
1630
- 1730 hrs IST
1900
- 2000 hrs SST/HKT
1100
- 1200 hrs BST
0600
- 0700 hrs US ET
Dial-in Numbers
Universal Access
Primary Access: (+91 22 6280 1562)
(+91 22 7115 8387)
Diamond pass link
Click hereto register
Toll Free Number
USA: 18667462133
UK: 08081011573
Hong Kong: 800964448
Singapore: 8001012045
Contact:
Investor Relations
Naveen Bansal
Ankit Bhembre
E-Mail:Investor.Relations@cipla.com
E-Mail:Investor.Relations@cipla.com
Attachments
Original Link
Original Document
Permalink
Disclaimer
Cipla Ltd. published this content on 11 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2023 07:39:10 UTC.
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
CIPLA LIMITED 
